Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

1

1 4

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Bladder and Ureter Cancer Report Coverage 9

2.2 Ureter Cancer – Overview 9

2.3 Bladder Cancer – Overview 9

3 Therapeutics Development 10

3.1 Ureter Cancer 10

3.2 Bladder Cancer 14

4 Therapeutics Assessment 34

4.1 Ureter Cancer 34

4.2 Bladder Cancer 41

5 Companies Involved in Therapeutics Development 58

5.1 Ureter Cancer 58

5.2 Bladder Cancer 61

6 Dormant Projects 125

6.1 Bladder Cancer 125

7 Discontinued Products 131

7.1 Bladder Cancer 131

8 Product Development Milestones 133

8.1 Ureter Cancer 133

8.2 Bladder Cancer 135

9 Appendix 149

9.1 Methodology 149

9.2 Coverage 149

9.3 Secondary Research 149

9.4 Primary Research 149

9.5 Expert Panel Validation 149

9.6 Contact Us 150

9.7 Disclaimer 1501.1 List of Tables

Table 1: Number of Products under Development for Ureter Cancer 10

Table 2: Number of Products under Development by Companies, Ureter Cancer 11

Table 3: Number of Products under Development by Universities/Institutes, Ureter Cancer 12

Table 4: Products under Development by Companies, Ureter Cancer 13

Table 5: Products under Development by Universities/Institutes, Ureter Cancer 13

Table 6: Number of Products under Development for Bladder Cancer 14

Table 7: Number of Products under Development by Companies, Bladder Cancer 16

Table 8: Number of Products under Development by Universities/Institutes, Bladder Cancer 21

Table 9: Products under Development by Companies, Bladder Cancer 22

Table 10: Products under Development by Universities/Institutes, Bladder Cancer 32

Table 11: Number of Products by Stage and Target, Ureter Cancer 35

Table 12: Number of Products by Stage and Mechanism of Action, Ureter Cancer 37

Table 13: Number of Products by Stage and Route of Administration, Ureter Cancer 39

Table 14: Number of Products by Stage and Molecule Type, Ureter Cancer 40

Table 15: Number of Products by Stage and Target, Bladder Cancer 42

Table 16: Number of Products by Stage and Mechanism of Action, Bladder Cancer 48

Table 17: Number of Products by Stage and Route of Administration, Bladder Cancer 55

Table 18: Number of Products by Stage and Molecule Type, Bladder Cancer 57

Table 19: Ureter Cancer – Pipeline by Altor BioScience Corp 58

Table 20: Ureter Cancer – Pipeline by Eisai Co Ltd 58

Table 21: Ureter Cancer – Pipeline by Exelixis Inc 59

Table 22: Ureter Cancer – Pipeline by GlaxoSmithKline Plc 59

Table 23: Ureter Cancer – Pipeline by MedImmune LLC 60

Table 24: Ureter Cancer – Pipeline by Merck & Co Inc 60

Table 25: Bladder Cancer – Pipeline by 4SC AG 61

Table 26: Bladder Cancer – Pipeline by Abivax SA 61

Table 27: Bladder Cancer – Pipeline by Adaptimmune Therapeutics Plc 62

Table 28: Bladder Cancer – Pipeline by ADC Therapeutics Sarl 62

Table 29: Bladder Cancer – Pipeline by Altor BioScience Corp 63

Table 30: Bladder Cancer – Pipeline by AndroScience Corp 63

Table 31: Bladder Cancer – Pipeline by ANP Technologies Inc 64

Table 32: Bladder Cancer – Pipeline by APIM Therapeutics AS 64

Table 33: Bladder Cancer – Pipeline by Archivel Farma SL 65

Table 34: Bladder Cancer – Pipeline by Argos Therapeutics Inc 65

Table 35: Bladder Cancer – Pipeline by Arno Therapeutics Inc 66

Table 36: Bladder Cancer – Pipeline by Array BioPharma Inc 66

Table 37: Bladder Cancer – Pipeline by Asana BioSciences LLC 67

Table 38: Bladder Cancer – Pipeline by Asieris Pharmaceuticals Co Ltd 67

Table 39: Bladder Cancer – Pipeline by Astellas Pharma Inc 68

Table 40: Bladder Cancer – Pipeline by Astex Pharmaceuticals Inc 68

Table 41: Bladder Cancer – Pipeline by AstraZeneca Plc 69

Table 42: Bladder Cancer – Pipeline by AVEO Pharmaceuticals Inc 69

Table 43: Bladder Cancer – Pipeline by Bavarian Nordic A/S 70

Table 44: Bladder Cancer – Pipeline by Bayer AG 70

Table 45: Bladder Cancer – Pipeline by Biocad 71

Table 46: Bladder Cancer – Pipeline by BioCancell Ltd 71

Table 47: Bladder Cancer – Pipeline by Biohaven Pharmaceutical Holding Company Ltd 72

Table 48: Bladder Cancer – Pipeline by Biomics Biotechnologies Co Ltd 72

Table 49: Bladder Cancer – Pipeline by Biotest AG 73

Table 50: Bladder Cancer – Pipeline by Boehringer Ingelheim GmbH 73

Table 51: Bladder Cancer – Pipeline by Bristol-Myers Squibb Co 74

Table 52: Bladder Cancer – Pipeline by Celgene Corp 74

Table 53: Bladder Cancer – Pipeline by Celldex Therapeutics Inc 75

Table 54: Bladder Cancer – Pipeline by Celprogen Inc 75

Table 55: Bladder Cancer – Pipeline by Celsion Corp 76

Table 56: Bladder Cancer – Pipeline by Celyad SA 76

Table 57: Bladder Cancer – Pipeline by Cleveland BioLabs Inc 77

Table 58: Bladder Cancer – Pipeline by Cold Genesys Inc 77

Table 59: Bladder Cancer – Pipeline by Corvus Pharmaceuticals Inc 78

Table 60: Bladder Cancer – Pipeline by CytomX Therapeutics Inc 78

Table 61: Bladder Cancer – Pipeline by Cytori Therapeutics Inc 79

Table 62: Bladder Cancer – Pipeline by Daiichi Sankyo Co Ltd 79

Table 63: Bladder Cancer – Pipeline by Eisai Co Ltd 80

Table 64: Bladder Cancer – Pipeline by Eleven Biotherapeutics Inc 80

Table 65: Bladder Cancer – Pipeline by Eli Lilly and Co 81

Table 66: Bladder Cancer – Pipeline by Elsalys Biotech SAS 82

Table 67: Bladder Cancer – Pipeline by EpiThany Inc 82

Table 68: Bladder Cancer – Pipeline by Esperance Pharmaceuticals Inc 83

Table 69: Bladder Cancer – Pipeline by Exelixis Inc 83

Table 70: Bladder Cancer – Pipeline by Exicure Inc 84

Table 71: Bladder Cancer – Pipeline by F. Hoffmann-La Roche Ltd 84

Table 72: Bladder Cancer – Pipeline by Five Prime Therapeutics Inc 85

Table 73: Bladder Cancer – Pipeline by Gene Signal International SA 85

Table 74: Bladder Cancer – Pipeline by Genentech Inc 861.2 List of Figures

Figure 1: Number of Products under Development for Ureter Cancer 10

Figure 2: Number of Products under Development by Companies, Ureter Cancer 11

Figure 3: Number of Products under Development by Universities/Institutes, Ureter Cancer 12

Figure 4: Number of Products under Development for Bladder Cancer 14

Figure 5: Number of Products under Development by Companies, Bladder Cancer 15

Figure 6: Number of Products under Development by Universities/Institutes, Bladder Cancer 20

Figure 7: Number of Products by Top 10 Targets, Ureter Cancer 34

Figure 8: Number of Products by Stage and Top 10 Targets, Ureter Cancer 34

Figure 9: Number of Products by Top 10 Mechanism of Actions, Ureter Cancer 36

Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Ureter Cancer 36

Figure 11: Number of Products by Routes of Administration, Ureter Cancer 38

Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Ureter Cancer 38

Figure 13: Number of Products by Molecule Types, Ureter Cancer 39

Figure 14: Number of Products by Stage and Molecule Types, Ureter Cancer 40

Figure 15: Number of Products by Top 10 Targets, Bladder Cancer 41

Figure 16: Number of Products by Stage and Top 10 Targets, Bladder Cancer 41

Figure 17: Number of Products by Top 10 Mechanism of Actions, Bladder Cancer 47

Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bladder Cancer 47

Figure 19: Number of Products by Routes of Administration, Bladder Cancer 54

Figure 20: Number of Products by Stage and Routes of Administration, Bladder Cancer 54

Figure 21: Number of Products by Top 10 Molecule Types, Bladder Cancer 56

Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bladder Cancer 56

Research Methodology

The research study released with title "Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Key Executives Interviewed

Research Programs/Design

Historical Data (2017-2022E)	Industry Trends Competition Analysis & Landscape By Company Product Launches Joint Venture & Partnerships Merger & Acquisitions Market Segment by Type by Application / End Users By Regions/ Geography	Value in Dollar Term Segment Revenue for Major & Emerging Players Market Share % Growth Rate Current Scenario Analysis Sales Volume by Key Players % Market Share & Position % Growth Rate
Market Factor Analysis	Market Environment Government Policy & Regulatory Factors Technological Changes Market Risks & Challenges	Market Drivers Market Maturity Indicators Impact of Cost Variance Growth Determinants
Market Forecast (2023F-2028F)	Overall Size (Value & Volume*) by Type by Application By Region / Country	Key Data (Value & Volume*) %Market Share %Growth Rate CAGR (2023-2028)

Market Size Estimation

Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.

To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.

HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Bladder and Ureter Cancer Drug Development Pipeline Review. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Bladder and Ureter Cancer Drug Development Pipeline Review who then work towards appointment generation.

Primary Data Collection

The primary research is performed by taking the interviews of executives of various companies dealing in the Bladder and Ureter Cancer Drug Development Pipeline Review as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.

Secondary Sources

The secondary resources considered in the Bladder and Ureter Cancer Drug Development Pipeline Review study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.

Market Breakdown and Data Triangulation

To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" .

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Research Journals Company Websites White Papers Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases HTF MI Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segment value
Qualitative Analysis	Influencing Trends Market Potential Market Risks and Opportunities Growth Drivers and Constraints Geographical Footprints Government Policies	Company Websites and Press Releases Survey Reports and Paid Databases Annual Reports Industry Associations HTF MI Database

Key Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments	Market Forecast (Value & Volume*) by Application, Type & Region / Country History and Forecast Market Size (Value & Volume) by Application Market Size by Regions, Status & Forecast	Market Share & Growth Rate by Type & Application Value by Key Business Segments % Growth Rate by Segments Growth Rate and Market Share by Regions Market Size Status & Forecast
Total Market	Overall Size, Status & Forecast	Market Size Status & Forecast

Format		Properties
1-User Access	The report is sent in PDF format. The report will be emailed to you.	This is a single user access license, allowing one specific user to access the report.
Site User	The study would be provided in PDF format. The report will be emailed to you.	This is a site license, allowing 1-10 employees within your organisation to access the report.
Enterprise User	The format of deliverable would be PDF and Excel.	This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report.